NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/30/2026
Back to search
Official data from USPTO
TELIX PHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
TELIX PHARMACEUTICALS
ST13
US500000079257540Class
5, 10
Filing
79257540
Registration
6908866
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
60
Latest update
07/30/2026
Classification
Registered
Trademark type
Word
Nice classes
5, 10
Filing date
03/14/2019
Registration date
11/29/2022
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/29/2022
Last transaction
07/30/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
AU
Examiner
SEVERSON, JUSTIN
Law office
M20
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Telix Pharmaceuticals Limited
Representatives
Andrew S. Ehard MERCHANT & GOULD P.C.
Technical classification
Nice Classes
Class 5Class 10
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Chemicals for pharmaceutical use for the treatmentpreventiondiagnosis of cancer; pharmaceutical drugs for the treatmentpreventiondiagnosis of cancer; pharmaceutical preparations for the treatment of cancer; radiopharmaceutical products for use in the treatmentpreventiondiagnosis of cancer
Class 10
Apparatus for administering pharmaceuticals for the treatmentpreventiondiagnosis of cancermedical apparatus for introducing pharmaceutical preparations into the human body for the treatmentpreventiondiagnosis of cancer; apparatus for medical purposes for the treatmentpreventiondiagnosis of cancerinjection needlesinjection syringesradiological apparatus for the treatmentpreventiondiagnosis of cancer; medical apparatus for the treatment of cancer; imaging apparatus for medical use for diagnosing cancer; drug delivery systems for the treatmentpreventiondiagnosis of cancerapplicators for pharmaceutical preparations sold without medication for use in the treatmentpreventiondiagnosis of cancer
Publications
History of USPTO decisions and trademark events.
60 publications found
NREP
NEW REPRESENTATIVE AT IB RECEIVED
02/26/2026
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
04/19/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
03/16/2023
FIMP
FINAL DISPOSITION PROCESSED
03/16/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
02/28/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
11/29/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
11/29/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/13/2022
PUBO
PUBLISHED FOR OPPOSITION
09/13/2022
GPNX
NOTIFICATION PROCESSED BY IB
09/11/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
08/24/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
08/24/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/24/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
08/15/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/10/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
08/10/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/10/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
08/10/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/10/2022
LIME
LIMITATION FROM THE IB - REQUEST EXAM REVIEW
08/09/2022
LIMS
LIMITATION OF GOODS/SERVICES FROM IB ENTERED
08/09/2022
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
10/03/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/24/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/23/2021
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
08/23/2021
LIMS
LIMITATION OF GOODS/SERVICES FROM IB ENTERED
08/15/2021
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
07/31/2021
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
03/12/2021
GNFR
FINAL REFUSAL E-MAILED
03/12/2021
CNFR
FINAL REFUSAL WRITTEN
03/12/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/18/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/17/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/17/2021
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
10/17/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/30/2020
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
09/30/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/17/2020
GNRT
NON-FINAL ACTION E-MAILED
08/17/2020
CNRT
NON-FINAL ACTION WRITTEN
08/17/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/13/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/13/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/13/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/12/2020
GNRT
NON-FINAL ACTION E-MAILED
01/12/2020
CNRT
NON-FINAL ACTION WRITTEN
01/12/2020
FINT
FINAL DECISION TRANSACTION PROCESSED BY IB
01/10/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/13/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/13/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/13/2019
RFNT
REFUSAL PROCESSED BY IB
07/12/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/14/2019
RFRR
REFUSAL PROCESSED BY MPU
06/14/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/30/2019
CNRT
NON-FINAL ACTION WRITTEN
05/29/2019
DOCK
ASSIGNED TO EXAMINER
05/23/2019
MAFR
APPLICATION FILING RECEIPT MAILED
05/14/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/09/2019
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
05/08/2019
SDRC
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
04/25/2019
Continuous trademark protection
Get notified about every new filing that threatens TELIX PHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.